Incannex Healthcare (NASDAQ:IXHL – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus…

Incannex reduced its net loss to $19.3 million in fiscal 2026 from $46.9 million a year earlier, mainly due to the absence of large warrant and debt-related losses, while ending the year with $67.7 million in cash following a $65.9 million financing inflow.

Incannex Healthcare Inc.

Incannex (Nasdaq: IXHL) announced that Alliance Global Partners has initiated equity research coverage with a BUY rating and a US$18.00 price target, in a report dated June 8, 2026 by analyst James Molloy.The coverage evaluates Incannex’s clinical pipeline, including IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder, and is expected by the company to broaden investor awareness. AGP has received compensation from Incannex for investment banking services.

YouTube video by Progress, Potential, and Possibilities

Reported Tuesday, Aug 11 - 9:20am EDT (TheFly subscription required to read more.)

New sleep apnea treatment achieves unprecedented 83% symptom reduction in clinical trial. Patient interviews reveal dramatic quality of life improvements. See full results.

Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding...

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Reported Wednesday, Sep 9 - 8:21am EDT (TheFly subscription required to read more.)

Click to view the official SEC document.

null

Incannex Healthcare (Nasdaq: IXHL) reported that the first patient has been dosed in DReAMzz, its Phase 2 crossover dose-optimization study of IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide for obstructive sleep apnea (OSA). All 14 U.S. trial sites have Institutional Review Board approval, drug product has been manufactured, and patient screening is underway.According to Incannex, IHL-42X previously showed statistically significant reductions in apnea-hypopnea index (AHI) versus placebo in the Phase 2 RePOSA study, with individual AHI reductions up to 83% and an exceptional safety profile. IHL-42X has received FDA Fast Track designation, and DReAMzz is intended to refine dose selection and support a planned Phase 3 program.

Reported Tuesday, Aug 25 - 8:51am EDT (TheFly subscription required to read more.)

Click to view the official SEC document.

Click to view the official SEC document.

Reported Thursday, Jul 23 - 8:07am EDT (TheFly subscription required to read more.)

Incannex Healthcare (Nasdaq: IXHL) has commenced participant screening in its DReAMzz Phase 2 randomized crossover dose-confirmation study of IHL-42X for obstructive sleep apnea (OSA). Initial clinical sites are approved and actively screening, with additional sites to begin as regulatory permissions are obtained.IHL-42X has FDA Fast Track designation, enabling more frequent FDA interactions and a potentially expedited review pathway. The DReAMzz study is designed to optimize dosing and assess both objective sleep metrics and patient-reported outcomes, building on earlier Phase 2 data that showed up to 83% reduction in Apnea-Hypopnea Index, significant improvements in fatigue and sleep-related impairment, and a favorable safety profile. OSA affects an estimated one billion people globally, and there are currently no FDA-approved oral pharmaceutical therapies for this condition.

Click to view the official SEC document.

Click to view the official SEC document.

MELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, an...